

February 6, 2019

The Manager – Listing
BSE Limited,
1st Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai 400001

The Manager – Listing
National Stock Exchange of India Ltd.
Exchange plaza, 5th Floor, Plot No.C/1, G Block
Bandra-Kurla Complex, Bandra (E),
Mumbai 400051

Dear Sir(s),

Sub: Outcome of the Board Meeting held on Wednesday, February 6, 2019

Ref: Scrip Code - BSE: 506820 / NSE: ASTRAZEN

At the Board Meeting of the Company held on Wednesday, February 6, 2019 the Board of Directors considered and approved the Unaudited Financial Results of the Company for the quarter ended December 31, 2018. The said Unaudited Financial Results together with the Limited Review report of the Statutory Auditors dated February 6, 2019 are enclosed herewith.

Please take the same on record.

Thanking you,

For AstraZeneca Pharma India Limited



Pratap Rudra
Company Secretary & Legal Counsel

AstraZeneca Pharma India Limited
 Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045
 Statement of Unaudited Financial results for the quarter and nine months ended 31 December 2018

SI No.	Particulars	Rs in lakhs except for earnings per share data					
		3 months ended 31/12/2018	Previous 3 months ended 30/09/2018	Corresponding 3 months ended in the previous year 31/12/2017	9 months ended 31/12/2018	9 months ended 31/12/2017	Previous year ended 31/03/2018
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue						
	a) Revenue from operations	21,519.40	16,136.08	12,853.86	53,799.16	42,126.27	57,198.92
	b) Other income	349.57	335.45	275.97	1,027.30	990.94	1,224.76
	Total revenue	21,868.97	16,471.53	13,129.83	54,826.46	43,117.21	58,423.68
2	Expenses						
	(a) Cost of materials consumed	1,684.01	946.41	778.77	4,317.76	1,638.94	2,788.01
	(b) Purchase of stock-in-trade	4,156.63	2,736.24	7,326.39	8,892.33	17,948.54	20,421.17
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	651.47	1,590.00	(4,260.83)	3,889.51	(5,883.26)	(5,099.57)
	(d) Excise duty	-	-	-	-	98.50	98.50
	(e) Employee benefits expense	5,211.18	4,495.17	3,711.65	14,013.63	10,845.72	15,353.09
	(f) Depreciation and amortisation expense	378.10	367.38	373.01	1,100.52	1,118.66	1,473.75
	(g) Selling, marketing and distribution expense	1,651.37	1,168.43	2,456.81	5,681.82	5,169.21	7,280.51
	(h) Other expenses	4,076.75	3,723.52	3,925.64	10,511.88	9,206.54	11,728.21
	(i) Finance cost	-	-	-	-	-	-
	Total expenses	17,809.51	15,027.15	14,311.44	48,407.45	40,142.85	54,043.67
3	Profit / (Loss) before exceptional and extraordinary items and tax (1-2)	4,059.46	1,444.38	(1,181.61)	6,419.01	2,974.36	4,380.01
4	Exceptional items	-	-	-	-	-	-
5	Profit / (Loss) before extraordinary items and tax (3+4)	4,059.46	1,444.38	(1,181.61)	6,419.01	2,974.36	4,380.01
6	Extraordinary items	-	-	-	-	-	-
7	Profit / (Loss) before tax (5+6)	4,059.46	1,444.38	(1,181.61)	6,419.01	2,974.36	4,380.01
8	Tax expense						
	- Current tax	1,114.91	437.87	(146.39)	1,816.26	704.99	899.74
	- Deferred tax	35.37	93.35	-	141.10	-	888.79
	Total tax expense	1,150.28	531.22	(146.39)	1,957.36	704.99	1,788.53
9	Profit / (Loss) for the period (7-8)	2,909.18	913.16	(1,035.22)	4,461.65	2,269.37	2,591.48
10	Other comprehensive income, net of Income tax						
	A. Items that will not be reclassified to profit or loss	(39.46)	(36.62)	243.27	90.43	282.60	(227.99)
	B. Items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other comprehensive income, net of income tax	(39.46)	(36.62)	243.27	90.43	282.60	(227.99)
	Total comprehensive income for the period (9+10)	2,869.72	876.54	(791.95)	4,552.08	2,551.97	2,363.49
11	Earnings per equity share of Rs 2/- each (basic and diluted)	11.64	3.65	(4.14)	17.85	9.08	10.37



g.s.

AstraZeneca Pharma India Limited
Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045
Statement of Unaudited Financial results for the quarter and nine months ended 31 December 2018

Notes:

- 1 The financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- 2 Ind AS 115 'Revenue from contracts with customers' mandatory for reporting periods beginning on or after 1 April 2018, replaces existing revenue recognition requirements. Under the modified retrospective approach, there were no significant adjustments required to the retained earnings as at 1 April 2018. The adoption of the standard did not have any impact on the financial results for the quarter and for the nine months ended 31 December 2018.
- 3 The Company has entered into a distribution agreement in respect of certain brands. Pursuant to this agreement, an upfront fee of Rs.2,131 lakhs received from a distributor has been recognized under 'Revenue from operations' during the quarter as it meets the point in time recognition criteria under IND AS 115. Consequently, as per arrangement, an amount of Rs.1,155.40 lakhs, being cumulative pre-launch expenses on new brands marketing and promotion incurred during the year has been charged to the income statement under appropriate headings.
- 4 The Company has identified 'Healthcare Segment' as its only reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly no segment information has been provided.
- 5 As previously disclosed, by way of a letter dated 1 March 2014, AstraZeneca Pharmaceuticals AB, the promoter of the Company had proposed a voluntary delisting of the Company's equity shares from the National Stock Exchange and the Bombay Stock Exchange. Such proposed delisting is subject to an on-going inquiry with SEBI and that inquiry has not yet been resolved. In any event, based on the passage of time, any potential future proposal for voluntary delisting of the Company would need to be conducted de novo.
- 6 Previous period's figures have been regrouped/reclassified, where necessary, to conform with the current period's presentation for the purpose of comparability.
- 7 This statement of financial results was reviewed and recommended by the Audit Committee of the Board and subsequently approved by the Board of Directors at their respective meetings held on 6 February 2019. The Statutory Auditors of the Company have carried out a limited review of this statement of financial results for the quarter ended 31 December 2018.

Place: Bangalore
Date: 06/02/2019

By Order of the Board of Directors
For AstraZeneca Pharma India Limited

Gagandeep Singh Bedi
Managing Director




Price Waterhouse & Co Chartered Accountants LLP

The Board of Directors
AstraZeneca Pharma India Limited
Block N1, 12th Floor,
Manyata Embassy Business Park,
Rachenahalli, Outer Ring Road,
Bengaluru- 560045

Independent Auditors' Report on Review of Interim results for the quarter ended December 31, 2018

1. We have reviewed the unaudited financial results of AstraZeneca Pharma India Limited (the "Company") for the quarter ended December 31, 2018, which are included in the accompanying 'Statement of unaudited results for the quarter and nine months ended December 31, 2018' (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations, 2015"), which has been initialled by us for identification purposes. The Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.
3. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Price Waterhouse & Co Chartered Accountants LLP
Firm Registration Number: 304026E/ E-300009



Pradip Kanakia
Partner
Membership Number: 039985

Place: Bengaluru
Date: February 6, 2019

Price Waterhouse & Co Chartered Accountants LLP, 5th Floor, Tower 'D', The Millenia, 1 & 2 Murphy Road
Ulsoor, Bangalore-560 008
T: +91 (80) 4079 5000, F: +91 (80) 4079 5222

Registered office and Head office: Plot No. Y-14, Block EP, Sector V, Salt Lake Electronic Complex, Bidhan Nagar, Kolkata 700 091

Price Waterhouse & Co. (a Partnership Firm) converted into Price Waterhouse & Co Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-4362) with effect from July 7, 2014. Post its conversion to Price Waterhouse & Co Chartered Accountants LLP, its ICAI registration number is 304026E/E-300009 (ICAI registration number before conversion was 304026E)